Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board of directors and management of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) on behalf of its investors [1][2]. Group 1: Investigation Details - The investigation aims to determine if the Verrica board has breached its fiduciary duties to shareholders [2]. - Shareholders are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [2]. Group 2: Firm Background - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). If you currently own shares of Verrica Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=6828 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg. ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). If you currently own shares of Verrica Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=6828 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg. ...

Chief Commercial Officer Chris Chapman, who joined in Q4, said priorities include simplifying product acquisition for patients and physicians and ensuring that once a diagnosis is made, a prescription is written. He reiterated that “watchful waiting” remains the largest competitive alternative in molluscum, though management also said the presence of a competitor (ZELSUVMI, mentioned during Q&A) validates demand for active treatment.Management said the company continues to invest in co-pay assistance to sup ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating OfficerJayson Rieger - President and CEOJohn Kirby - Interim Chief Financial OfficerKevin Gardner - Managing DirectorConference Call ParticipantsDennis Ding - AnalystDev Prasad - SVP, Biotech Equity Research AnalystKemp Dolliver - Director of Research and Senior AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare Anal ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating OfficerJayson Rieger - President and CEOJohn Kirby - Interim Chief Financial OfficerKevin Gardner - Managing DirectorConference Call ParticipantsDev Prasad - SVP, Biotech Equity Research AnalystGeorgia Bank - AnalystKemp Dolliver - Director of Research and Senior AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare Ana ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Speaker8Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may b ...

Product Development and Approval - YCANTH (VP-102) was approved by the FDA in July 2023 for the treatment of molluscum in patients aged two years and older, with a commercial launch in August 2023[18]. - YCANTH (VP-102) received New Chemical Entity status in March 2024, providing a minimum of five years of regulatory exclusivity[21]. - The FDA granted a new HCPCS Level II code J7354 for YCANTH (VP-102), effective April 1, 2024, enhancing market access for the product[51]. - The FDA approved YCANTH (VP-102) for the treatment of molluscum in July 2023, and it became commercially available in August 2023[168]. - The regulatory approval process for product candidates is lengthy and unpredictable, with no approvals obtained for any candidates other than YCANTH (VP-102) for molluscum[210]. - The FDA may issue an approval letter for a New Drug Application (NDA) after evaluating all related information, including inspection reports and advisory committee recommendations[113]. - A complete response letter from the FDA may require additional documentation or testing before reconsidering the NDA application[114]. - The FDA may impose restrictions on marketing or require additional studies based on post-marketing surveillance results, potentially impacting product distribution[120]. - The company must demonstrate safety and efficacy through extensive preclinical testing and clinical trials before obtaining regulatory approvals[203]. Market Potential and Financials - Approximately 6 million people in the U.S. are estimated to have molluscum, with an annual diagnosis rate of about 1 million, representing a total addressable market of over $1 billion[20]. - The total addressable U.S. market for common warts is estimated to be over $1 billion, with approximately 22 million people affected[26]. - The company expects to continue incurring significant expenses and operating losses until revenue from YCANTH (VP-102) is sufficient to fund operations[169]. - The company has $30.1 million in cash and cash equivalents as of December 31, 2025, raising substantial doubt about its ability to continue as a going concern within one year[177]. - The market potential for YCANTH (VP-102) may not be as large as expected, affecting revenue projections[167]. - The company may face challenges in obtaining adequate reimbursement for its products, which could impact revenue generation[167]. - The company’s financial position may be adversely affected by risks related to the development and commercialization of its product candidates[162]. Clinical Trials and Research - VP-315 is being developed for the treatment of basal cell carcinoma (BCC), with an estimated global market of $6.7 billion in 2021, projected to grow to $11.5 billion by 2028[28]. - In a Phase 2 trial for VP-315, approximately 51% of tumors achieved complete histologic clearance, with an overall tumor size reduction of 86%[32]. - The company has initiated a Phase 3 clinical program for VP-315, with two studies planned involving approximately 100 subjects each[33]. - The Phase 2 trial of VP-315 for basal cell carcinoma (BCC) showed that approximately 51% of tumors achieved complete histologic clearance, with an overall tumor size reduction of 86%[62]. - The FDA provided feedback supporting an efficient Phase 3 program for VP-315, which includes two studies of approximately 100 subjects each with a primary endpoint of complete clearance at week 14[66]. - The company is evaluating cost and logistics for the initiation of the VP-315 Program into Phase 3 clinical trials and may explore non-dilutive strategic partnerships for funding[66]. - Patient enrollment in clinical trials is critical and may be affected by various factors, including perceived risks and benefits of the product candidates[197]. - The company may experience significant delays or failures in clinical trials, which could prevent or delay regulatory approval and commercialization[203]. Collaborations and Partnerships - Torii Pharmaceutical Co., Ltd. is collaborating on the development of YCANTH (VP-102) for common warts, with costs split equally between the companies[36]. - The company has received $38.0 million in milestone revenue from Torii under the collaboration agreement, with potential additional payments of up to $32.0 million contingent on regulatory and sales milestones[85]. - The Torii Agreement requires Torii to use commercially reasonable efforts to obtain regulatory approval and commercialize licensed products in Japan[84]. - The company has an exclusive, royalty-bearing license for Lytix technology to develop VP-315, with potential milestone payments up to $111.0 million based on development and sales achievements[94]. - The Lytix Agreement allows the company to negotiate for additional exclusive licenses for VP-315 in other dermatological indications[93]. Regulatory and Compliance Challenges - The company must navigate extensive regulatory requirements for drug development, which require significant time and financial resources[96]. - Drug manufacturers must register with the FDA and comply with current Good Manufacturing Practices (cGMP), which includes ongoing inspections and compliance requirements[121]. - The federal Anti-Kickback Statute prohibits inducements for purchasing or recommending drugs, with strict compliance required to avoid legal repercussions[132]. - The False Claims Act prohibits presenting false claims for payment to the federal government, with significant legal consequences for violations[134]. - The company is subject to various federal and state healthcare laws, which may complicate compliance efforts and expose it to significant penalties if violations occur[140][139]. - The company faces significant scrutiny regarding pharmaceutical pricing practices, with potential impacts from the Medicare Drug Price Negotiation Program, which may reduce reimbursement rates significantly[143][144]. Operational and Human Resources - As of December 31, 2025, the company employed 76 full-time employees, all located in the United States, with no union representation[154]. - The company’s human capital resources strategy focuses on attracting and retaining talent through equity incentive plans to enhance shareholder value[155]. - The company maintains product liability insurance consistent with industry standards, but rising costs may affect future coverage availability[156]. - The company relies on third-party suppliers for raw materials and applicator components for YCANTH (VP-102), which poses a risk to business operations[167]. Risks and Uncertainties - The company faces high risks in product development, with the possibility that product candidates may never obtain regulatory approval[189]. - The company may need to raise additional capital to meet financial obligations and pursue business objectives, which could lead to dilution of existing shareholders[180]. - Delays in clinical trials could significantly increase costs and hinder the ability to generate product revenues[193]. - The potential for regulatory authorities to withdraw approvals or require additional warnings could adversely impact the company's reputation and market acceptance[207]. - Changes in manufacturing methods or formulations may lead to increased costs or delays in clinical trials, affecting the overall development timeline[206]. - The company may need to conduct additional clinical trials post-approval, which could incur significant costs and delay commercialization[213].

Financial Performance - YCANTH® net revenue increased by 130% to $15.3 million in 2025, compared to $6.6 million in 2024[2][16] - Total revenue for the company reached $35.6 million in 2025, up from $7.6 million in the prior year[2] - In Q4 2025, total revenue increased to $5.092 million, up from $344, representing a growth of 1,376% year-over-year[27] - Product revenue for the year ended December 31, 2025, was $15.285 million, compared to $6.574 million in 2024, marking a 132% increase[29] - License and collaboration revenue for 2025 was $20.3 million, primarily from milestone payments and commercial supplies related to the partnership with Torii Pharmaceutical[18] Expenses and Losses - Selling, general and administrative expenses decreased by over 40% to $35.2 million in 2025, down from $58.8 million in 2024[2][18] - The company reported a net loss of $17.9 million, or $1.68 per share, for the twelve months ended December 31, 2025, compared to a net loss of $76.6 million, or $14.78 per share, for the same period in 2024[18] - Research and development expenses were $8.9 million for the full year 2025, down from $11.8 million in 2024[18] - Operating expenses for Q4 2025 totaled $12.284 million, compared to $11.754 million in Q4 2024, reflecting a 4.5% increase[27] - The net loss for Q4 2025 was $8.074 million, a significant improvement from a net loss of $16.202 million in Q4 2024[27] - The company reported a basic and diluted net loss per share of $0.57 for Q4 2025, compared to $2.41 in Q4 2024[27] Assets and Liabilities - Total assets decreased to $47.131 million as of December 31, 2025, down from $54.134 million in 2024[31] - Current liabilities were $17.322 million as of December 31, 2025, compared to $30.363 million in 2024, indicating a reduction of 42.9%[31] - The company has no outstanding debt and its cash runway is extended into the first quarter of 2027[2][4] Clinical Development - The first patient was dosed in the Phase 3 study of YCANTH for common warts in December 2025, with a second study expected to start in mid-2026[2][12] - The company is advancing VP-315 toward a Phase 3 program for basal cell carcinoma, with a 97% objective response rate observed in earlier trials[11][6] - Verrica plans to expand the clinical development of YCANTH in Europe and other international markets[25] - The company has entered a worldwide license agreement with Lytix Biopharma AS to develop VP-315 for non-melanoma skin cancers[24] Product Information - YCANTH® (VP-102) is the first FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million people in the U.S., primarily children[21][24] - The number of YCANTH dispensed applicator units grew by 99% to 51,296 in 2025, compared to 25,773 units in 2024[2]

Core Insights - Verrica Pharmaceuticals reported significant growth in 2025, with total revenue increasing to $35.6 million from $7.6 million in 2024, marking a 368% increase [1][3] - The company achieved a 130% growth in net revenue for its product YCANTH, reaching $15.3 million in 2025, while reducing selling, general, and administrative expenses by over 40% [1][3] - The number of YCANTH dispensed applicator units grew by 99%, totaling 51,296 units in 2025 compared to 25,773 units in 2024 [1][3] Financial Performance - For the fourth quarter of 2025, product revenue was $3.7 million, up from $0.3 million in the same quarter of 2024 [14][17] - The company reported a net loss of $8.1 million for Q4 2025, a significant reduction from a net loss of $16.2 million in Q4 2024 [14][17] - For the full year 2025, the net loss was $17.9 million, compared to a net loss of $76.6 million in 2024, indicating improved financial health [17][19] Product Development and Regulatory Progress - The company is advancing its novel oncolytic peptide VP-315 towards a Phase 3 program for basal cell carcinoma, with supportive data indicating potential abscopal effects [1][5] - The first patient was dosed in a Phase 3 study for YCANTH targeting common warts in December 2025, with plans to initiate a second Phase 3 study in the US and Japan in mid-2026 [1][5] - Verrica gained alignment with the European Medicines Agency, allowing for a streamlined regulatory path for YCANTH's approval in the EU without additional clinical studies [1][4] Market Expansion and Partnerships - The company has launched its first international partnership for YCANTH with Torii Pharmaceutical in Japan, which has already received regulatory approval for the treatment of molluscum contagiosum [4][11] - The company is exploring additional commercialization partnerships to enhance funding and revenue opportunities, particularly following the positive feedback from European regulators [4][5] Operational Efficiency - The company has no outstanding debt and has extended its cash runway into the first quarter of 2027, indicating a strong liquidity position [1][3] - Selling, general, and administrative expenses for the full year 2025 were $35.2 million, down from $58.8 million in 2024, reflecting improved operational efficiency [17][19]